Pfizer disputes suit claiming Zoloft doesn't work

by The Associated Press

(AP)—The maker of Zoloft is being sued in an unusual case alleging the popular antidepressant has no more benefit than a dummy pill. The federal lawsuit, filed in California, argues that patients who took it should be reimbursed for their costs.

Zoloft's maker, ., disagrees. It says clinical studies and the experience of millions of patients and their doctors over two decades prove Zoloft is effective.

Pfizer and four psychiatry experts interviewed by The Associated Press call the lawsuit frivolous.

But the plaintiff, Laura Plumlee, says Zoloft didn't help her during three years of treatment. Her attorney, R. Brent Wisner, argues the shouldn't have approved Zoloft because Pfizer didn't publish some studies that found the drug about as effective as a placebo.

1 /5 (1 vote)
add to favorites email to friend print save as pdf

Related Stories

Pfizer anti-smoking drug has heart risks: US

Jun 16, 2011

US regulators said Thursday that the label on Pfizer's anti-smoking drug Chantix must be changed to warn of a slightly higher risk of heart problems in patients who already have cardiovascular disease.

FDA adds heart warning to Pfizer anti-smoking pill

Jun 16, 2011

(AP) -- Federal health regulators are warning doctors and patients that Pfizer's anti-smoking drug Chantix may slightly increase the risk of heart attack and other cardiovascular problems.

FDA panel backs Pfizer drug for kidney cancer

Dec 07, 2011

(AP) -- A panel of advisers to the Food and Drug Administration voted Wednesday that the benefits of a Pfizer kidney cancer drug outweigh its risks, according to a company spokeswoman.

Citing liver damage, Pfizer withdraws Thelin

Dec 10, 2010

(AP) -- Pfizer Inc. said Friday it is pulling its blood pressure drug Thelin off the market and stopping all clinical trials because the drug can cause fatal liver damage.

FDA clears Pfizer drug for advanced kidney cancer

Jan 27, 2012

(AP) -- The Food and Drug Administration has approved a new Pfizer drug for patients with advanced kidney cancer that has spread to other parts of the body despite treatment with at least one previous drug.

Recommended for you

Mirabegron for overactive bladder: Added benefit not proven

6 hours ago

Mirabegron (trade name: Betmiga) has been approved since December 2012 for the treatment of adults with overactive bladder. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products ...

Novartis Japan admits concealing drug side effects

Sep 01, 2014

The Japanese unit of Swiss pharma giant Novartis has admitted it did not report more than 2,500 cases of serious side effects in patients using its leukaemia and other cancer drugs, reportedly including some fatalities.

Most US babies get their vaccines, CDC says

Aug 28, 2014

(HealthDay)—The vast majority of American babies are getting the vaccines they need to protect them from serious illnesses, federal health officials said Thursday.

User comments